Navigation Links
ABA Conference in Chicago Provides Litigators First Look at DNA Technology That Can Save Millions in Workers Comp and Toxic Tort Cases
Date:12/5/2007

CHICAGO, Dec. 5 /PRNewswire/ -- Each year, major corporations and their insurance companies pay out hundreds of millions of dollars in litigation settlements and jury awards for mass-tort cases by workers claiming to have been harmed by exposure to chemicals. Now a new DNA technology promises to weed out frivolous claims from the legitimate ones, saving companies and their insurers millions on such payouts and prompting reasonable settlements and resolutions.

Dr. Bruce Gillis, CEO of the genomics research group, The Cytokine Institute (TCI), is presenting a tutorial on the application of DNA lab-based evidence in workers' compensation and civil litigation at the American Bar Association's "National Program on National Trends" TIPS Staff Counsel CLE for 2008.

For the first time, litigators will tour TCI's affiliate laboratories at the University of Illinois College of Medicine at Chicago (UIC), on March 26 and 28, 2008, where they will gain hands-on experience of the new genomics- based technology, msds1(TM). The technology is already being used in some civil courts to weed out baseless lawsuits by identifying on a cellular level if an individual has suffered injury due to a specific chemical or toxic exposure.

By analyzing how 36,000 parameters of an individual's DNA are affected by specific chemicals -- including benzene, chromium, asbestos and formaldehyde -- this technology can determine with 99.9% certainty if a person was injuriously exposed to a particular toxin, thereby offering an objective methodology for providing scientifically-based evidence. Companies facing class-action and mass-tort lawsuits immediately benefit by knowing how chemicals and toxins in their workplace affect human health and the environment.

Sponsored by the ABA, and co-sponsored by the Workers' Injury Law & Advocacy Group, The College of Workers' Compensation Lawyers, The National Conference of the Administrative Law Judiciary, The American College of Occupational and Environmental Medicine (ACOEM), and The American Medical Association (AMA), the conference will be held March 26-28, 2008 at the InterContinental Hotel in Chicago, IL. It will assemble legal experts in Workers' Compensation law, products liability law, toxic tort litigation, employment law, and occupational medicine. For more information visit http://www.abanet.org/tips.

With an M.D. degree from the University of Illinois College of Medicine, a M.P.H. degree from the Harvard University School of Public Health, and medical residencies in Occupational Medicine and Medical Toxicology and in Internal Medicine, Dr. Bruce Gillis brings over 30 years of medical expertise to his position as founder and CEO of The Cytokine Institute.

The Cytokine Institute provides a variety of consulting services in the area of litigation support, risk management, human resources, medical toxicology and healthcare. The organization developed DNA-based technologies, which provide vital information that is germane to Material Safety Data Sheets, the recently enacted REACH protocol and numerous other international, and United States rules and regulations concerning potentially harmful substances.

CONTACT: For more information or an interview with Dr. Gillis and his team, visit http://www.cytokineinstitute.com or contact Leslie Valenza at (202) 258-3223 or lvalenza@levick.com.


'/>"/>
SOURCE The Cytokine Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
2. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
3. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
4. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
5. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
6. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
7. AtriCure to Present at Roth Capital Partners 2007 New York Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. MDS to Present at Thomas Weisel Partners Healthcare Conference
10. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
11. AMICAS to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: